Alliance Pharma
Alliance Pharma plc, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative healthcare products. Founded in 1998, the company has established a strong presence in various operational regions, including Europe and Asia, focusing on prescription medicines and over-the-counter products. With a diverse portfolio that includes unique formulations and niche therapeutic areas, Alliance Pharma is recognised for its commitment to quality and patient care. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Notably, Alliance Pharma has garnered accolades for its effective product range, which addresses unmet medical needs and enhances patient outcomes.
DitchCarbon Score
How does Alliance Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance Pharma's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alliance Pharma's reported carbon emissions
In 2023, Alliance Pharma reported total carbon emissions of approximately 50,138,000 kg CO2e globally. This figure includes 3,000 kg CO2e from Scope 2 emissions, primarily from purchased electricity, and a significant 50,125,000 kg CO2e from Scope 3 emissions, which encompass various categories such as purchased goods and services (43,034,000 kg CO2e) and upstream transportation and distribution (2,894,000 kg CO2e). For the UK operations in 2023, the total emissions were about 101,050 kg CO2e, with Scope 2 emissions accounting for 45,580 kg CO2e and Scope 3 emissions contributing 55,470 kg CO2e, primarily from upstream transportation and distribution. In 2022, the global emissions were slightly lower at approximately 48,026,000 kg CO2e, with Scope 1 emissions at 2,000 kg CO2e, Scope 2 emissions at 52,000 kg CO2e, and Scope 3 emissions at 47,973,000 kg CO2e. The UK operations reported total emissions of about 91,420 kg CO2e, including 1,570 kg CO2e from Scope 1 and 44,460 kg CO2e from Scope 2. Alliance Pharma has not set specific reduction targets or initiatives as part of their climate commitments, and there are no cascading data from a parent organization. The company continues to monitor and report its emissions, adhering to industry standards for transparency and accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | 0,000 | 0,000 | - |
| Scope 2 | 107,000 | 00,000 | 00,000 | 00,000 | 0,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alliance Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
